These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22804100)

  • 21. Penetration of moxifloxacin into liver tissue.
    Justinger C; Schilling MK; Kees MG; Kauffels A; Hirschmann K; Kopp B; Kees F; Kollmar O
    Int J Antimicrob Agents; 2012 Jun; 39(6):505-9. PubMed ID: 22526014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats.
    Cárceles CM; Villamayor L; Escudero E; Marín P; Fernández-Varón E
    Vet J; 2007 Mar; 173(2):452-5. PubMed ID: 16377219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state.
    Breilh D; Jougon J; Djabarouti S; Gordien JB; Xuereb F; Velly JF; Arvis P; Landreau V; Saux MC
    J Chemother; 2003 Dec; 15(6):558-62. PubMed ID: 14998080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment.
    Barth J; Jäger D; Mundkowski R; Drewelow B; Welte T; Burkhardt O
    J Antimicrob Chemother; 2008 Sep; 62(3):575-8. PubMed ID: 18515790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration.
    Zhang L; Li L; Shi W; Liu S; Liang X; Ye Z; Wang WJ; Zhang B; Li R; Chen Y; Yu C; Zhuo L; Wang X
    Int J Antimicrob Agents; 2013 Sep; 42(3):244-9. PubMed ID: 23876335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum concentrations and pharmacokinetics of moxifloxacin in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.
    Wiesner G; Martin K; Gertler R; Braun SL; Tassani P; Lange R; Gruber M
    Int J Antimicrob Agents; 2013 May; 41(5):473-6. PubMed ID: 23481660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty.
    Holland EJ; Lane SS; Kim T; Raizman M; Dunn S
    Cornea; 2008 Apr; 27(3):314-9. PubMed ID: 18362660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration.
    Fuhrmann V; Schenk P; Jaeger W; Ahmed S; Thalhammer F
    J Antimicrob Chemother; 2004 Oct; 54(4):780-4. PubMed ID: 15347636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic variables of moxifloxacin in healthy male camels following intravenous and intramuscular administration.
    Abd El-Aty AM; Goudah A; Shah SS; Shin HC; Shimoda M; Shim JH
    J Vet Pharmacol Ther; 2007 Dec; 30(6):586-91. PubMed ID: 17991229
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience.
    Pranger AD; van Altena R; Aarnoutse RE; van Soolingen D; Uges DR; Kosterink JG; van der Werf TS; Alffenaar JW
    Eur Respir J; 2011 Oct; 38(4):888-94. PubMed ID: 21310881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia.
    Simon N; Sampol E; Albanese J; Martin C; Arvis P; Urien S; Lacarelle B; Bruguerolle B
    Clin Pharmacol Ther; 2003 Oct; 74(4):353-63. PubMed ID: 14534522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitreal penetration of oral moxifloxacin in humans.
    Lott MN; Fuller JJ; Hancock HA; Singh J; Singh H; McGwin G; Marcus DM
    Retina; 2008 Mar; 28(3):473-6. PubMed ID: 18327141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration.
    Fernández-Varón E; Bovaira MJ; Espuny A; Escudero E; Vancraeynest D; Cárceles CM
    J Vet Pharmacol Ther; 2005 Aug; 28(4):343-8. PubMed ID: 16050813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.
    Florian JA; Tornøe CW; Brundage R; Parekh A; Garnett CE
    J Clin Pharmacol; 2011 Aug; 51(8):1152-62. PubMed ID: 21228407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statistical characteristics of moxifloxacin-induced QTc effect.
    Yan LK; Zhang J; Ng MJ; Dang Q
    J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moxifloxacin pharmacokinetics in horses and disposition into phagocytes after oral dosing.
    Gardner SY; Davis JL; Jones SL; LaFevers DH; Hoskins MS; McArver EM; Papich MG
    J Vet Pharmacol Ther; 2004 Feb; 27(1):57-60. PubMed ID: 14995968
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin.
    Vasavada AR; Gajjar D; Raj SM; Vasavada V; Vasavada V
    J Cataract Refract Surg; 2008 Aug; 34(8):1379-82. PubMed ID: 18655991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock.
    Pletz MW; Bloos F; Burkhardt O; Brunkhorst FM; Bode-Böger SM; Martens-Lobenhoffer J; Greer MW; Stass H; Welte T
    Intensive Care Med; 2010 Jun; 36(6):979-83. PubMed ID: 20336279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty.
    Fukuda M; Yamada M; Kinoshita S; Inatomi T; Ohashi Y; Uno T; Shimazaki J; Satake Y; Maeda N; Hori Y; Nishida K; Kubota A; Nakazawa T; Shimomura Y
    Adv Ther; 2012 Apr; 29(4):339-49. PubMed ID: 22529026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort.
    Majcher-Peszynska J; Sass M; Schipper S; Czaika V; Gussmann A; Lobmann R; Mundkowski RG; Luebbert C; Kujath P; Ruf BR; Koch H; Schareck W; Klar E; Drewelow B;
    Eur J Clin Pharmacol; 2011 Feb; 67(2):135-42. PubMed ID: 20871984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.